The stock of IN8bio Inc (INAB) has gone up by 1.63% for the week, with a 46.79% rise in the past month and a -52.00% drop in the past quarter. The volatility ratio for the week is 12.42%, and the volatility levels for the past 30 days are 19.84% for INAB. The simple moving average for the past 20 days is 4.08% for INAB’s stock, with a -58.70% simple moving average for the past 200 days.
Is It Worth Investing in IN8bio Inc (NASDAQ: INAB) Right Now?
INAB has 36-month beta value of 0.01. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for INAB is 32.04M, and currently, short sellers hold a 3.13% ratio of that float. The average trading volume of INAB on November 15, 2024 was 1.08M shares.
INAB) stock’s latest price update
IN8bio Inc (NASDAQ: INAB)’s stock price has soared by 6.09 in relation to previous closing price of 0.32. Nevertheless, the company has seen a gain of 1.63% in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trial INB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers and a prospective parallel observational cohort as a control Closed private placement for net proceeds of $11.6 Million in October 2024 extending cash runway through 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer, today reported financial results for the third quarter ended September 30, 2024, and recent corporate highlights.
Analysts’ Opinion of INAB
Many brokerage firms have already submitted their reports for INAB stocks, with Laidlaw repeating the rating for INAB by listing it as a “Buy.” The predicted price for INAB in the upcoming period, according to Laidlaw is $7.50 based on the research report published on March 18, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see INAB reach a price target of $14. The rating they have provided for INAB stocks is “Buy” according to the report published on August 30th, 2022.
INAB Trading at 13.58% from the 50-Day Moving Average
After a stumble in the market that brought INAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.45% of loss for the given period.
Volatility was left at 19.84%, however, over the last 30 days, the volatility rate increased by 12.42%, as shares surge +46.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.56% lower at present.
During the last 5 trading sessions, INAB rose by +1.63%, which changed the moving average for the period of 200-days by -74.15% in comparison to the 20-day moving average, which settled at $0.3228. In addition, IN8bio Inc saw -75.65% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for INAB
Current profitability levels for the company are sitting at:
- -8.5 for the present operating margin
- 0.5 for the gross margin
The net margin for IN8bio Inc stands at -8.5. The total capital return value is set at -2.58. Equity return is now at value -241.97, with -151.16 for asset returns.
Based on IN8bio Inc (INAB), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -4.56. The debt to equity ratio resting at 0.64. The interest coverage ratio of the stock is -54.03.
Currently, EBITDA for the company is -28.5 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 6.89. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.
Conclusion
To put it simply, IN8bio Inc (INAB) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
